Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Rajalla Prewitt

Child & Adolescent Psychiatry Cleveland, OH Medical Doctor

NPI 1770644064 CMS profile 34645

2322 E 22Nd St Ste 200, Cleveland, OH 44115

Open in the dashboard

General payments

$1,959

89 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Rajalla Prewitt of Cleveland, OH is reported in the CMS Open Payments database as having received $1,959 across 89 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $427 15
2023 General $815 35
2022 General $137 8
2020 General $202 10
2019 General $379 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajalla Prewitt
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Rajalla Prewitt were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Rajalla Prewitt Child & Adolescent Psychiatry median Middle half National median
2019 $379 $129 $42–$419 $163
2020 $202 $81 $28–$226 $114
2021 $0 $115 $31–$326 $132
2022 $137 $124 $40–$382 $149
2023 $815 $130 $45–$420 $160
2024 $427 $141 $42–$490 $164
2025 $0 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Otsuka America Pharmaceutical, Inc. $410 15 payments
  2. Lundbeck LLC $284 15 payments
  3. Teva Pharmaceuticals USA, Inc. $276 9 payments
  4. Neurocrine Biosciences, Inc. $217 13 payments
  5. Alkermes, Inc. $201 9 payments
  6. Janssen Pharmaceuticals, Inc $179 7 payments
  7. AbbVie, Inc. $109 5 payments
  8. ITI, Inc. $89 5 payments
  9. Sunovion Pharmaceuticals Inc. $51 3 payments
  10. Indivior Inc. $41 2 payments
  11. Other $102 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,847 88 payments
  2. Education $111 1 payment
Products named General payments · program years 2019–2024
  1. REXULTI Psychiatry $388 14 payments
  2. REXULTI Psychiatry $247 13 payments
  3. ABILIFY MAINTENA $202 10 payments
  4. ARISTADA Cns $158 7 payments
  5. ARISTADA Cns $158 7 payments
  6. ARISTADA Cns $158 7 payments
  7. ARISTADA Cns $158 7 payments
  8. INVEGA SUSTENNA $114 4 payments
  9. VRAYLAR $109 5 payments
  10. INGREZZA $109 7 payments
  11. Other $922 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

358

Median for Psychiatry: 574

Drug cost

$110,953

Median for Psychiatry: $27,624

Branded share of claims

21.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 13 $105,794
Aripiprazole Generic 13 $798
Alprazolam Generic 22 $735
Doxepin Hcl Generic 23 $705
Duloxetine Hcl Generic 17 $457
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 15 $456
Gabapentin Generic 30 $317
Hydroxyzine Hcl Generic 18 $268
Lithium Carbonate Er Lithium Carbonate Brand 12 $194
Clonazepam Generic 22 $174

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $82
$82 — —
REXULTI
  • Lundbeck LLC $64
  • Otsuka America Pharmaceutical, Inc. $16
$80 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $43
$43 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $32
$32 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

89 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record